Xbrane Biopharma AB (XBRANE) Fair Value & Analysis
Healthcare · SE · Market cap 222M SEK
Fair value as of: Jul 16, 2026
From 9 valuation models · updated today
Share price +7.0% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 5.66 – kr 36.78 · fair‑value band kr 6.68 – kr 13.21 · the kr 10.70 price screens above the kr 8.90 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Xbrane Biopharma AB (XBRANE) currently trades at kr 10.70, while our model-based Fair Value estimate is kr 8.90, implying the stock looks roughly 16.8% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at 76.5M SEK. Revenue declined 81.4% year over year. It earns a return on equity of -20.4%. The balance sheet holds a net cash position of 28.3M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 6.68 (bear case) to kr 13.21 (bull case); at kr 10.70, the current price sits within that range. The share trades about 72% below its 52-week high and 97% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside, at -17%, XBRANE screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Xbrane Biopharma AB reported revenue of kr 152M in FY2025 versus kr 11.5M in FY2021, a compound +90.6%/yr. Reported net income was kr 127M in FY2025.
Is XBRANE fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $935.38 | $382.64 | -59% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Xbrane Biopharma AB (XBRANE) undervalued?
What is the fair value of XBRANE?
What is the quality score of XBRANE?
What is the revenue of Xbrane Biopharma AB (XBRANE)?
What is the net profit margin of XBRANE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Xbrane Biopharma AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.